Melatonin effects on EEG activity during non-rapid eye movement sleep in mild-to-moderate Alzheimer´s disease: a pilot study

Cruz‐Aguilar, Manuel Alejandro; Ramírez‐Salado, Ignacio; Hernández‐González, Marisela; Guevara, Miguel Ángel; Rio, Jahaziel Molina del

doi:10.1080/00207454.2020.1750392

Cited by 12 publications

(7 citation statements)

References 56 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…From the most recent randomized clinical trials conducted in the past year and using antioxidants in neurodegenerative diseases found in this review, two of them used melatonin in different neurodegenerative contexts, including Alzheimer’s disease and Parkinson’s disease. Both of them reported interesting significant changes among groups [ 53 , 56 ], such as a significant decrease of lipoperoxides, nitric oxide metabolites, and carbonyl groups in proteins in plasma samples from patients with Parkinson’s disease receiving melatonin compared with the placebo group. Conversely, catalase activity was increased significantly in comparison with the placebo group.…”

Section: Discussionmentioning

confidence: 99%

“…Finally, the widely known hormone melatonin and its derived effects have also been recently used in Alzheimer’s disease clinical trials. In the most recent clinical trial, non-rapid eye movement sleep onset related to melatonin administration in Alzheimer’s disease patients has been associated with significant changes in the beta and gamma bands during non-rapid eye movement sleep [ 53 ]. However, such findings do not explicitly report any clinical- or cognition-related improvement, probably due to the short-term period of treatment applied (2 nights) ( Table 2 ).…”

Section: Mitochondrial Antioxidant Interventions In Chronic Neurodege...mentioning

confidence: 99%

See 1 more Smart Citation

Antioxidant Therapeutic Strategies in Neurodegenerative Diseases

Morén

deSouza

Giraldo

et al. 2022

IJMS

View full text Add to dashboard Cite

The distinguishing pathogenic features of neurodegenerative diseases include mitochondrial dysfunction and derived reactive oxygen species generation. The neural tissue is highly sensitive to oxidative stress and this is a prominent factor in both chronic and acute neurodegeneration. Based on this, therapeutic strategies using antioxidant molecules towards redox equilibrium have been widely used for the treatment of several brain pathologies. Globally, polyphenols, carotenes and vitamins are among the most typical exogenous antioxidant agents that have been tested in neurodegeneration as adjunctive therapies. However, other types of antioxidants, including hormones, such as the widely used melatonin, are also considered neuroprotective agents and have been used in different neurodegenerative contexts. This review highlights the most relevant mitochondrial antioxidant targets in the main neurodegenerative disorders including Alzheimer’s disease, Parkinson’s disease, and Huntington’s disease and also in the less represented amyotrophic lateral sclerosis, as well as traumatic brain injury, while summarizing the latest randomized placebo-controlled trials.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Mitochondrial Antioxidant Interventions In Chronic Neurodege...mentioning

confidence: 99%

Antioxidant Therapeutic Strategies in Neurodegenerative Diseases

Morén

deSouza

Giraldo

et al. 2022

IJMS

View full text Add to dashboard Cite

show abstract

“…neurodegenerative diseases, 25,26 and schizophrenia, 27,28 and can improve user interfaces for augmented reality/virtual reality (AR/VR) systems. [29][30][31][32] However, the fundamental challenge in reliably extracting biopotential signals through wearable electrodes is to design an electrode enjoying both the signal quality of traditional wet electrodes and the comfort of the dry ones.…”

Section: Progress and Potentialmentioning

confidence: 99%

Multimodal Smart Eyewear for Longitudinal Eye Movement Tracking

Homayounfar

Rostaminia

Kiaghadi

et al. 2020

Matter

View full text Add to dashboard Cite

We present a first-of-its-kind fabric hydrogel electrode that is reusable and washable, does not cause skin irritation, and can be continuously operated for upward of 8 h without losing signal integrity. Second, we report an ion-based fabric pressure sensor that measures pulse waveforms when placed on the face. We decorate a lightweight eye mask with these novel fabric electrodes to create a portable detection platform named ''Chesma,'' which can wirelessly track eye motion and pulse in natural environments over long periods of time.

show abstract

“…Melatonin reduced sleep latency to all stages of NREM and was associated with increased generation and coherence of slow EEG bands according to Cruz‐Aguilar et al. ( 2020 ).…”

Section: Discussionmentioning

confidence: 89%

“…As well as begin studied in the context of optimising circadian rhythm, the effect of melatonin on NREM sleep was explored by Cruz‐Aguilar et al. ( 2020 ) in a further analysis of data from the same study described in Cruz‐Aguilar et al. ( 2018 ).…”

Section: Resultsmentioning

confidence: 99%

Pharmacological and non‐pharmacological interventions to enhance sleep in mild cognitive impairment and mild Alzheimer's disease: A systematic review

Blackman

Swirski

Clynes

et al. 2020

Journal of Sleep Research

View full text Add to dashboard Cite

Suboptimal sleep causes cognitive decline and probably accelerates Alzheimer's Disease (AD) progression. Several sleep interventions have been tested in established AD dementia cases. However early intervention is needed in the course of AD at Mild Cognitive Impairment (MCI) or mild dementia stages to help prevent decline and maintain good quality of life. This systematic review aims to summarize evidence on sleep interventions in MCI and mild AD dementia. Seven databases were systematically searched for interventional studies where ≥ 75% of participants met diagnostic criteria for MCI/mild AD dementia, with a control group and validated sleep outcome measures. Studies with a majority of participants diagnosed with Moderate to Severe AD were excluded. After removal of duplicates, 22,133 references were returned in two separate searches (August 2019 and September 2020). 325 full papers were reviewed with 18 retained. Included papers reported 16 separate studies, total sample (n = 1,056), mean age 73.5 years. 13 interventions were represented: Cognitive Behavioural Therapy – Insomnia (CBT‐I), A Multi‐Component Group Based Therapy, A Structured Limbs Exercise Programme, Aromatherapy, Phase Locked Loop Acoustic Stimulation, Transcranial Stimulation, Suvorexant, Melatonin, Donepezil, Galantamine, Rivastigmine, Tetrahydroaminoacridine and Continuous Positive Airway Pressure (CPAP). Psychotherapeutic approaches utilising adapted CBT‐I and a Structured Limbs Exercise Programme each achieved statistically significant improvements in the Pittsburgh Sleep Quality Index with one study reporting co‐existent improved actigraphy variables. Suvorexant significantly increased Total Sleep Time and Sleep Efficiency whilst reducing Wake After Sleep Onset time. Transcranial Stimulation enhanced cortical slow oscillations and spindle power during daytime naps. Melatonin significantly reduced sleep latency in two small studies and sleep to wakefulness transitions in a small sample. CPAP demonstrated efficacy in participants with Obstructive Sleep Apnoea. Evidence to support other interventions was limited. Whilst new evidence is emerging, there remains a paucity of evidence for sleep interventions in MCI and mild AD highlighting a pressing need for high quality experimental studies exploring alternative sleep interventions.

show abstract

Melatonin effects on EEG activity during non-rapid eye movement sleep in mild-to-moderate Alzheimer´s disease: a pilot study

Cited by 12 publications

References 56 publications

Antioxidant Therapeutic Strategies in Neurodegenerative Diseases

Antioxidant Therapeutic Strategies in Neurodegenerative Diseases

Multimodal Smart Eyewear for Longitudinal Eye Movement Tracking

Pharmacological and non‐pharmacological interventions to enhance sleep in mild cognitive impairment and mild Alzheimer's disease: A systematic review

Contact Info

Product

Resources

About